Bifidobacterium affected the correlation between gut microbial composition, SCFA metabolism, and immunity in mice with DNFB-induced atopic dermatitis

Abstract

The prevalence of atopic dermatitis (AD) has increased and a therapeutic strategy using probiotic intervention has been reported. The effects of different Bifidobacterium (B. breve, B. bifidum, B. animalis, B. infants, and B. adolescentis) on gut microbial changes were explored in 2,4-dinitrofluorobenzene (DNFB)-induced AD, a T helper type 2-dominant allergic disease. Oral administration of Bifidobacterium suppressed skin thickening and mast cell infiltration, blocked pro-inflammatory cytokines (IL-4, CCL11, IL-13, and CCL22), increased IL-10 and IFN-γ, and modulated the microbiome and ecology in the gut. Based on 16S rRNA results, DNFB treatment resulted in gut microbial dysbiosis, characterized by a decrease in the proportion of Firmicutes and an increase in Bacteroidetes. The core microbiome related to AD were also observed (Dorea, Prevotella, Sutterella, Odoribacter, and Pseudomonas). B. breve and B. bifidum treatments increased the relative abundance of Adlercreutzia, Streptococcus, Lactobacillus, Anaerostipes, and Anaerotruncus. The functional modules involved in fructose and mannose metabolism, propanoate metabolism, and fatty acid biosynthesis were upregulated, and these might be related to immune regulation and short-chain fatty acids (SCFA) production. Taken together, these results suggested that Bifidobacterium treatments affected gut microbial composition and structure, altered gut microbial ecosystem, and these alterations were closely associated with inflammation and SCFA production.